keyword
MENU ▼
Read by QxMD icon Read
search

Psoriasis definition

keyword
https://www.readbyqxmd.com/read/30219765/what-should-be-the-primary-target-of-treat-to-target-in-psoriatic-arthritis
#1
Laura C Coates, Ennio Lubrano, Fabio Massimo Perrotta, Paul Emery, Philip G Conaghan, Philip S Helliwell
OBJECTIVE: Recommendations regarding "treat to target" in psoriatic arthritis (PsA) have stated that the target should be remission or inactive disease. Potential definitions include very low disease activity (VLDA), PsA Disease Activity Score (PASDAS) near remission, Disease Activity Index for PsA (DAPSA) or clinical DAPSA (cDAPSA) remission. Our aim was to investigate the proportion of patients who fulfill these definitions and how much residual active disease remained. METHODS: This analysis used 2 datasets: first, trial data from the Tight Control of PsA (TICOPA) study, which included 206 patients with recent-onset (< 2 yrs) PsA receiving standard and biological disease-modifying antirheumatic drugs (DMARD); and second, an observational clinical dataset from Italy of patients receiving biological DMARD...
September 15, 2018: Journal of Rheumatology
https://www.readbyqxmd.com/read/30214149/focus-on-biosimilar-etanercept-bioequivalence-and-interchangeability
#2
REVIEW
Fabrizio Cantini, Maurizio Benucci
Background: The recent approval of reference etanercept (re-ETN) biosimilars SB4, GP2015, and HD203 produced relevant changes in the management of rheumatoid arthritis (RA), psoriatic arthritis, and ankylosing spondylitis due to the considerably lower cost of these products and the consequent savings. Aims: To review the pharmacodynamics, pharmacokinetics, efficacy, and safety of ETN biosimilars when employed as first-line therapy or after transition from re-ETN...
2018: Biologics: Targets & Therapy
https://www.readbyqxmd.com/read/30171803/trends-in-the-prevalence-and-incidence-of-psoriasis-and-psoriatic-arthritis-in-ontario-canada-a-population-based-study
#3
Lihi Eder, Jessica Widdifield, Cheryl F Rosen, Richard Cook, Ker-Ai Lee, Raed Alhusayen, J Michael Paterson, Stephanie Y Cheng, Shirin Jabbari, Willemina Campbell, Sasha Bernatsky, Dafna D Gladman, Karen Tu
OBJECTIVE: To estimate the prevalence and incidence of psoriasis and psoriatic arthritis (PsA) over time in Ontario, Canada. METHODS: We performed a population-based study of Ontario health administrative data using validated case definitions for psoriasis and PsA. We computed the crude and age/sex-standardized cumulative prevalence and incidence of psoriasis from 2000 to 2015. RESULTS: Among the 10,774,802 individuals aged 20 years and older residing in Ontario in 2015, we identified 273,238 and 18,655 patients with psoriasis and PsA, respectively, equating to cumulative prevalence estimates of 2...
September 1, 2018: Arthritis Care & Research
https://www.readbyqxmd.com/read/30135860/interaction-of-psoriasis-and-bullous-diseases
#4
REVIEW
Teruki Dainichi, Kenji Kabashima
Patients with psoriasis are frequently complicated with autoimmune bullous diseases, especially, pemphigoid diseases. It has been known that one-third cases of anti-laminin gamma1 pemphigoid, formerly anti-p200 pemphigoid, are associated with psoriasis whereas bullous pemphigoid is the most frequently associated bullous disease in psoriasis cases regardless of the lack of detectable levels of the accompanying anti-laminin gamma1 autoantibodies. Despite several suggestions, however, the definitive reason of the striking association of psoriasis and these autoimmune bullous diseases remains elusive...
2018: Frontiers in Medicine
https://www.readbyqxmd.com/read/30130618/incidence-and-risk-of-inflammatory-bowel-disease-in-patients-with-psoriasis-a-nationwide-20-year-cohort-study
#5
Alexander Egeberg, Jacob P Thyssen, Johan Burisch, Jean-Frederic Colombel
In psoriasis patients, incidence rates (IRs) of Crohn's disease (CD) and ulcerative colitis (UC) have been increased in epidemiological studies and certain clinical trials, yet the association remains poorly understood. We studied a 20-year nationwide cohort of 235,038 Danish adults with psoriasis and a 1:1 matched reference group. Less than 1% of psoriasis patients developed CD or UC during follow-up. IRs of CD were highest for younger women with psoriasis and patients with concurrent psoriatic arthritis (PsA), whereas men with psoriasis had particularly high IRs of UC compared with their non-psoriasis peers...
August 18, 2018: Journal of Investigative Dermatology
https://www.readbyqxmd.com/read/30075809/do-ethnicity-degree-of-family-relationship-and-the-spondyloarthritis-subtype-in-affected-relatives-influence-the-association-between-a-positive-family-history-for-spondyloarthritis-and-hla-b27-carriership-results-from-the-worldwide-asas-cohort
#6
Miranda van Lunteren, Alexandre Sepriano, Robert Landewé, Joachim Sieper, Martin Rudwaleit, Désirée van der Heijde, Floris van Gaalen
BACKGROUND: The Assessment of SpondyloArthritis international Society (ASAS) defines a positive family history (PFH) of spondyloarthritis (SpA) as the presence of ankylosing spondylitis (AS), acute anterior uveitis (AAU), reactive arthritis (ReA), inflammatory bowel disease (IBD), and/or psoriasis in first-degree relatives (FDR) or second-degree relatives (SDR). In two European cohorts, a PFH of AS and AAU, but not other subtypes, was associated with human leukocyte antigen B27 (HLA-B27) carriership in patients suspected of axial SpA (axSpA)...
August 3, 2018: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/30035729/the-role-of-the-stress-in-the-development-of-severe-forms-of-psoriasis-case-report
#7
A Daschuk, Ye Dobrzhanskaya, N Pustovaya
The purpose of the study was to follow the casual mechanism of exacerbation, progression and formation of severe forms of psoriasis, as well as the progression of cutaneous manifestation of psoriasis with the definition of the role of stress response in their development by analyzing features of the psoriasis dynamics on the example of reviewing clinical case in anamnesis. MATERIALS AND METHODS: Examination of the psychosomatic condition and stress-making immunoneuroendocrine system of the patient with psoriasis was conducted at the beginning of disease and in the remission period of psoriasis...
June 2018: Georgian Medical News
https://www.readbyqxmd.com/read/30033578/ex-vivo-fluorescence-confocal-microscopy-for-intraoperative-real-time-diagnoses-of-cutaneous-inflammatory-diseases-a-preliminary-study
#8
Laura Bertoni, Paola Azzoni, Camilla Reggiani, Alessandra Pisciotta, Gianluca Carnevale, Johanna Chester, Shaniko Kaleci, Luca Reggiani Bonetti, Anna Maria Cesinaro, Caterina Longo, Giovanni Pellacani
Ex vivo fluorescence confocal microscopy (FCM) is an innovative imaging tool that can be used intraoperatively to obtain real-time images of untreated excised tissue with almost histologic resolution. As inflammatory diseases often share overlapping clinical features, histopathology evaluation is required for dubious cases, delaying definitive diagnoses, and therefore therapy. This study identifies key-features at ex vivo FCM for differential diagnoses of cutaneous inflammatory diseases, in particular, psoriasis, eczema, lichen planus and discoid lupus erythematosus...
July 22, 2018: Experimental Dermatology
https://www.readbyqxmd.com/read/29904911/metabolic-syndrome-and-risk-of-incident-psoriasis-prospective-data-from-the-hunt-study-norway
#9
I Snekvik, T I L Nilsen, P R Romundstad, M Saunes
BACKGROUND: Metabolic syndrome has been associated with psoriasis in cross-sectional studies, but data from prospective studies are sparse. OBJECTIVES: To prospectively examine whether metabolic syndrome and its components are associated with risk of incident psoriasis in a large population-based study using objective measurements of cardiovascular disease risk factors. METHODS: We used data from two consecutive surveys of the HUNT Study, Norway (HUNT2, 1995-1997, and HUNT3, 2006-08)...
June 14, 2018: British Journal of Dermatology
https://www.readbyqxmd.com/read/29874363/core-outcome-sets-for-psoriasis-clinical-trials-definition-consensus-and-acceptance
#10
Bruce E Strober, Kenneth B Gordon
No abstract text is available yet for this article.
June 6, 2018: JAMA Dermatology
https://www.readbyqxmd.com/read/29852521/generalized-pustular-psoriasis-a-model-disease-for-specific-targeted-immunotherapy-systematic-review
#11
REVIEW
Alexander Boehner, Alexander A Navarini, Kilian Eyerich
Generalized pustular psoriasis (GPP) is a rare, multisystemic skin disease characterized by recurrent episodes of pustulation. GPP can be life-threatening and is often difficult to treat. In the era of precision medicine in dermatology, GPP stands exemplary for both challenges and chances-while new treatments offer great hope, there is urgent need for better definition and stratification of this severe and heterogeneous disease. Our objective was to systematically review the literature for evidence of efficacy of targeted immunotherapy and their mode of action in the context of clinical phenotype, classification and pathogenesis of adult GPP...
May 31, 2018: Experimental Dermatology
https://www.readbyqxmd.com/read/29848153/efficacy-and-survival-of-biologic-agents-in-psoriasis-a-practical-real-life-12-year-experience-in-a-french-dermatology-department
#12
Hélène Roche, Kevin Bouiller, Eve Puzenat, Elise Deveza, Blandine Roche, Fabien Pelletier, Alison van de Laak, Anne Sophie Dupond, Charlée Nardin, François Aubin
BACKGROUND: Drug survival in a real-life setting is critical to long-term use of biologics for psoriasis. OBJECTIVE: We describe our 12-year experience with biologics in psoriasis patients. PATIENTS AND METHODS: All patients treated with biologics including infliximab, adalimumab, etanercept and ustekinumab for psoriasis vulgaris between January 2005 and December 2016 were retrospectively analyzed. RESULTS: In total, 545 treatment series were administered to 269 patients, including 211 treatment series with adalimumab, 135 with etanercept, 77 with infliximab and 122 with ustekinumab...
May 31, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/29792371/biologics-monitoring-incongruity-between-recommendations-and-clinician-monitoring-trends
#13
Anish Nadkarni, Kimberly Hyde, Leah A Cardwell, Steven R Feldman
BACKGROUND: Biologics are a commonly used treatment for moderate to severe psoriasis. Monitoring laboratory test overuse provide little definitive benefit to patients. OBJECTIVE: We aim to query a Humana database to gain insight regarding current dermatologist laboratory monitoring practices for psoriasis patients on biologics. METHODS: Data were obtained from the Humana database. Our cohort included 333 patients with primary ICD-9 diagnosis of psoriasis (696...
May 24, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/29771924/obesity-and-response-to-anti-tumor-necrosis-factor-%C3%AE-agents-in-patients-with-select-immune-mediated-inflammatory-diseases-a-systematic-review-and-meta-analysis
#14
REVIEW
Siddharth Singh, Antonio Facciorusso, Abha G Singh, Niels Vande Casteele, Amir Zarrinpar, Larry J Prokop, Eduardo L Grunvald, Jeffrey R Curtis, William J Sandborn
OBJECTIVES: We sought to evaluate the association between obesity and response to anti-tumor necrosis factor-α (TNF) agents, through a systematic review and meta-analysis. METHODS: Through a systematic search through January 24, 2017, we identified randomized controlled trials (RCTs) or observational studies in adults with select immune-mediated inflammatory diseases-inflammatory bowel diseases (IBD), rheumatoid arthritis (RA), spondyloarthropathies (SpA), psoriasis and psoriatic arthritis (PsA)-treated with anti-TNF agents, and reporting outcomes, stratified by body mass index (BMI) categories or weight...
2018: PloS One
https://www.readbyqxmd.com/read/29730888/patient-perceptions-of-clear-almost-clear-skin-in-moderate-to-severe-plaque-psoriasis-results-of-the-clear-about-psoriasis-worldwide-survey
#15
A Armstrong, S Jarvis, W-H Boehncke, M Rajagopalan, P Fernández-Peñas, R Romiti, A Bewley, B Vaid, L Huneault, T Fox, M Sodha, R B Warren
BACKGROUND: Therapeutic advances have made the achievement of clear/almost clear skin possible for many patients with moderate-to-severe plaque psoriasis. OBJECTIVE: To determine patient perceptions of the impact of psoriasis and of attaining clear/almost clear skin. METHODS: Global survey of patients with moderate-to-severe psoriasis. RESULTS: A total of 8338 patients from 31 countries participated. The majority (57%) had not achieved self-assessed clear/almost clear skin with their current therapy, and 56% of those who had not met this goal believed it would be impossible to do so...
May 6, 2018: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29729165/modern-specific-features-and-therapy-of-psoriasis-and-arthropathic-psoriasis-courses
#16
Orysya O Syzon, Marianna O Dashko, Ulyana V Fedorova
OBJECTIVE: Introduction:Psoriasis affects about 2% of population. In 30-40% of occurrences arthropathic psoriasis (AP) is diagnosed and it leads to 11-19% of disability cases development. Recent studies have shown that psoriasis is often synergistically combined with herpesvirus of the 1st and 2nd type, which, according to many scientists, determines the severity, frequency of recurrences, and the course of this dermatosis. Recently, new biomarkers, i.e. a system of small ribonucleic microRNA acids, have been described...
2018: Wiadomości Lekarskie: Organ Polskiego Towarzystwa Lekarskiego
https://www.readbyqxmd.com/read/29718756/healthcare-resource-utilization-and-costs-among-psoriasis-patients-treated-with-biologics-overall-and-by-disease-severity
#17
Mwangi J Murage, Amanda Anderson, Susan A Oliveria, Deborah Casso, Clement K Ojeh, Talia M Muram, Joseph F Merola, Andre B Araujo
AIMS: To describe healthcare resource utilization (HCRU) and costs among biologic-treated psoriasis patients in the US, overall and by disease severity. MATERIALS AND METHODS: IQVIA PharMetrics Plus administrative claims data were linked with Modernizing Medicine Data Services Electronic Health Record data and used to select adult psoriasis patients between April 1, 2010 and December 31, 2014. Eligible patients were classified by disease severity (mild, moderate, severe) using a hierarchy of available clinical measures...
August 2018: Journal of Medical Economics
https://www.readbyqxmd.com/read/29675414/spondyloarthritis-acute-anterior-uveitis-and-fungi-updating-the-catterall-king-hypothesis
#18
Martin Laurence, Mark Asquith, James T Rosenbaum
Spondyloarthritis is a common type of arthritis which affects mostly adults. It consists of idiopathic chronic inflammation of the spine, joints, eyes, skin, gut, and prostate. Inflammation is often asymptomatic, especially in the gut and prostate. The HLA-B*27 allele group, which presents intracellular peptides to CD8+ T cells, is by far the strongest risk factor for spondyloarthritis. The precise mechanisms and antigens remain unknown. In 1959, Catterall and King advanced a novel hypothesis explaining the etiology of spondyloarthritis: an as-yet-unrecognized sexually acquired microbe would be causing all spondyloarthritis types, including acute anterior uveitis...
2018: Frontiers in Medicine
https://www.readbyqxmd.com/read/29652832/sympathetic-nerve-hyperactivity-in-the-spleen-causal-for-nonpathogenic-driven-chronic-immune-mediated-inflammatory-diseases-imids
#19
REVIEW
Denise L Bellinger, Dianne Lorton
Immune-Mediated Inflammatory Diseases (IMIDs) is a descriptive term coined for an eclectic group of diseases or conditions that share common inflammatory pathways, and for which there is no definitive etiology. IMIDs affect the elderly most severely, with many older individuals having two or more IMIDs. These diseases include, but are not limited to, type-1 diabetes, obesity, hypertension, chronic pulmonary disease, coronary heart disease, inflammatory bowel disease, and autoimmunity, such as rheumatoid arthritis (RA), Sjőgren's syndrome, systemic lupus erythematosus, psoriasis, psoriatic arthritis, and multiple sclerosis...
April 13, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29566966/considerations-for-the-definition-of-remission-criteria-in-psoriatic-arthritis
#20
REVIEW
Philip J Mease, Laura C Coates
OBJECTIVES: Psoriatic arthritis (PsA) is an autoimmune disease that can cause progressive structural damage of the joints and irreversible disability. The potentially achievable results of biologic therapy for PsA has led to the view that disease remission should be the goal of treatment. However, the heterogeneity of disease manifestations and need for validated outcome measures makes defining remission in PsA challenging. This article evaluates proposed criteria for defining remission in PsA and discusses how these criteria can be applied in clinical practice...
June 2018: Seminars in Arthritis and Rheumatism
keyword
keyword
110315
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"